Triple therapy versus biologic therapy for Active Rheumatoid Arthritis a cost-effectiveness analysis

Nick Bansback, Ciaran Phibbs, Huiying Sun, James R. O'Dell, Mary Brophy, Edward C. Keystone, Sarah Leatherman, Ted R. Mikuls, Aslam H. Anis, William Ayoub, Gilles Boire, Vivian Bykerk, Andrew Chow, Keith Colburn, David Daikh, John Davis, Hani El-Gabalawy, Jennifer Elliott, Joseph Fanciullo, Samardeep GuptaKeri Hannagan, Raymond Hausch, Erika Holmberg, Amy Joseph, Salahuddin Kazi, Peter Kent, Gail Kerr, Karen Kolba, C. Kent Kwoh, Maren Mahowald, Liam Martin, Thomas Olenginski, Jay Persselin, Mahfooz Peshimam, Lynne Peterson, Pamela Prete, David Pugliese, Virginia Reddy, Andreas Reimold, Jude Rodrigues, H. Ralph Schumacher, J. Carter Thorne, Joanne Valeriano-Marcet, Cynthia Weaver, Ciaran S. Phibbs

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Triple therapy versus biologic therapy for Active Rheumatoid Arthritis a cost-effectiveness analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences